Last A$4.26 AUD
Change Today +0.05 / 1.19%
Volume 689.0K
MSB On Other Exchanges
As of 2:10 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

mesoblast ltd (MSB) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/1/13 - A$6.80
52 Week Low
07/28/14 - A$3.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MESOBLAST LTD (MSB)

Related News

No related news articles were found.

mesoblast ltd (MSB) Details

Mesoblast Limited, a clinical development company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The company’s cell-based core technologies include its Mesenchymal Precursor Cell (MPC) technology platform, which is used to develop products derived from bone marrow and adipose tissue sources; Dental Pulp Stem Cells technology; and expanded Hematopoietic Stem Cells technology. It develops products for intravenous administration to target unmet medical needs in diseases of excessive inflammation and immune dysfunction, including type 2 diabetes, inflammatory joint diseases, and inflammatory lung diseases; MPC treatment therapies for diseases of the spine; adult stem cell-based therapies for the treatment of cardiovascular diseases, including congestive heart failure; and products for treating eye diseases, neurologic diseases, and cord blood expansion. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPC products in various diseases, including cardiovascular diseases and neurologic conditions. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

76 Employees
Last Reported Date: 08/29/13
Founded in 2004

mesoblast ltd (MSB) Top Compensated Officers

Founder, Chairman of Scientific Advisory Boar...
Total Annual Compensation: A$1.7M
Compensation as of Fiscal Year 2013.

mesoblast ltd (MSB) Key Developments

National Institutes of Health and Mesoblast Limited Enter into Agreement for 120-Patient Trial in End-Stage Heart Failure

Mesoblast Limited announced the signing of an agreement with the United States National Institutes of Health's National Heart, Lung and Blood Institute to collaborate on a trial using Mesoblast's proprietary adult stem cell therapy to treat patients with advanced heart failure requiring an implantable left ventricular assist device to maintain circulatory support. The National Institute of Neurological Disorders and Stroke, part of the NIH, and the Canadian Institutes for Health Research are also supporting this trial. The key objectives of using Mesoblast's Mesenchymal Precursor Cells (MPCs) in end-stage heart failure patients are to improve heart muscle function sufficiently to reduce the need for LVAD support, and to reduce the long-term complications of LVAD implantation which result in recurrent hospitalizations.

Mesoblast Limited Presents at 2014 Bioshares Biotech Summit, Jul-19-2014 10:30 AM

Mesoblast Limited Presents at 2014 Bioshares Biotech Summit, Jul-19-2014 10:30 AM. Venue: Rydges Lakeland Resort, Queenstown, New Zealand. Speakers: Nick Cameron, to consider 'Making Sense of Cell Therapy Products and Business Models'.

Mesoblast Limited Announces Address Changed of its Registered Office and Principal Place of Business

Mesoblast Limited has changed address of its registered office and principal place of business to the Level 38, 55 Collins Street, Melbourne, VIC 3000, Australia. This change is effective June 23, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSB:AU A$4.26 AUD +0.05

MSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.91 USD +0.27
Biorestorative Therapies Inc $0.30 USD 0.00
BioTime Inc $2.83 USD -0.02
IntelliCell BioSciences Inc $0.0014 USD 0.0001
International Stem Cell Corp $0.11 USD +0.003
View Industry Companies

Industry Analysis


Industry Average

Valuation MSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.5x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MESOBLAST LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at